DMT is a psychoactive alkaloid present in Ayahuasca, a hallucinogenic brew traditionally used by indigenous communities in South America.
Can ayahuasca, a psychoactive brew used traditionally in South America, be used to treat depression and other mental illnesses? Biotech builder ATAI Life Sciences is setting up a subsidiary to find out: Viridia Life Sciences.
In this episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr. Matthew
Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day
The use of biomarkers could help doctors tailor doses for each patient and improve their
Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential
There is no excerpt because this is a protected post.
In the inaugural episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr.
Clinical trials are being carried out to test the efficacy of arketamine as therapy for
Join Richard Simon, Chair at YPO (Young Presidents Organization) Psychedelic Medicines for Mental Health Group,
Compass Pathway’s recent raise of $80M to expand research into the clinical uses of psilocybin only affirms that no coronavirus is going to dampen efforts to make these treatments legal and widely accessible.
Born out of the desire to create psychedelic compounds more scalable than psilocybin, biotech startup EntheogeniX wants to make new, short-acting drugs that are “pharmacologically cleaner” than magic mushrooms, so more patients and practitioners can benefit from their use.
A couple days ago, ATAI Life Sciences, a biotech company developing psychedelic medicines for a variety of mental health indication, announced that it had raised $24 million in a convertible note financing round.
Billionaire investor Peter Thiel made his first investment in ATAI Life Sciences, a German startup that’s looking into ways of using magic mushrooms and other psychedelics to treat mental-health disorders.